Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Boehringer Ingelheim
Federal Trade Commission

Generated: November 21, 2017

DrugPatentWatch Database Preview

Details for Patent: 5,424,471

« Back to Dashboard

Summary for Patent: 5,424,471

Title: Crystalline amifostine compositions and methods of the preparation and use of same
Abstract:The present invention relates to a sterile, stable vacuum dried crystalline amifostine composition and, optionally, pharmaceutically acceptable excipient(s). Typically, the crystalline compositions of the present invention exhibit enhanced stability at temperatures ranging from about 4.degree. C. to about ambient temperature for a period of at least 2 years relative to existing solid vacuum dried amorphous amifostine preparations. The reconstituted compositions of the present invention are suitable for administration to humans as a radio- or chemoprotecting agent.
Inventor(s): Kennedy; Paul E. (Phoenixville, PA), Rajewski; Roger A. (Lawrence, KS), Baldoni; John M. (Glenmore, PA)
Assignee: U.S. Bioscience, Inc. (West Conshohocken, PA)
Application Number:08/099,298
Patent Claim Types:
see list of patent claims
Composition; Process; Formulation; Use; Dosage form;

No matches for this query

International Patent Family for Patent: 5,424,471

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Finland950420► Subscribe
Spain2215992► Subscribe
European Patent Office1764103► Subscribe
Czech Republic9500230► Subscribe
Germany69333453► Subscribe
Denmark0655917► Subscribe
European Patent Office0655917► Subscribe
European Patent Office1243272► Subscribe
Czech Republic284417► Subscribe
China1307870► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
US Department of Justice
Queensland Health
Harvard Business School
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

Google Plus